Connect with us
  • tg

Stock Markets

ORYZON Receives Intention to Grant Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

letizo News

Published

on

MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has issued an intention to grant communication for Oryzon’s European patent application EP20712565.9 entitled Methods of treating borderline personality disorder related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder (BPD) and schizophrenia.

The intention to grant is a formal communication from the EPO in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. This European patent, once granted, will not expire until at least 2040, excluding any potential patent term extensions that may provide additional protection. Decision to grant communications have also recently been received in corresponding patent applications in Japan and Mexico, and patent applications are pending in other relevant markets.

We are delighted to have received this decision to grant from the EPO. This European patent application further strengthens the company’s patent portfolio for vafidemstat in CNS, and together with our European patent application allowed earlier this year covering the use of vafidemstat for the treatment of aggression and social withdrawal, will significantly prolong vafidemstat’s commercial life in Europe, said Neus Virgili, Oryzon’s Chief IP Officer.

About Oryzon  
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS and iadademstat in oncology, in several Phase II clinical trials. The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com

About Vafidemstat
Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer’s disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong, and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders (REIMAGINE) and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 has been observed after 6 and 12 months of treatment, and the pilot, small-scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where anti-inflammatory activity has also been observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Vafidemstat is being investigated in neuropsychiatric disorders in two double-blind, randomized, placebo-controlled Phase IIb trials: one in schizophrenia, named EVOLUTION (recruitment ongoing), and another one in Borderline Personality disorder (BPD), named PORTICO, finalized and with published topline data (final data will be presented at ECNP-2024 in September). Based on PORTICO’s results, the company has requested an End-of-Phase II meeting with the FDA to discuss options for a registrational Phase III trial in BPD. The company is also deploying a CNS precision medicine approach with vafidemstat in genetically-defined patient subpopulations of certain CNS disorders and is preparing a clinical trial in Kabuki Syndrome patients. The company is also exploring the clinical development of vafidemstat in other neurodevelopmental syndromes.

FORWARD-LOOKING STATEMENTS    
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events, or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

Spain  Oryzon  IR, US  IR & Media, Europe  
Patricia Cobo/Mario Cordera  Emili Torrell  Ashley R. Robinson  Sandya von der Weid  
Atrevia  Chief Business Officer  LifeSci Advisors, LLC  LifeSci Advisors, LLC  
+34 91 564 07 25  
+34 673 33 97 65  
+34 93 515 1313  +1 617 430 7577  +41 78 680 05 38    
pcobo@atrevia.com  
mcordera@atrevia.com  
etorrell@oryzon.com  arr@lifesciadvisors.com  svonderweid@lifesciadvisors.com  

Source: Oryzon Genomics, S.A.

Stock Markets

A-Mark Precious Metals extends credit agreement to 2026

letizo News

Published

on

EL SEGUNDO, CA – A-Mark Precious Metals, Inc. (NASDAQ:), a leading wholesaler of precious metals, has amended its existing credit agreement, extending the facility’s termination date and modifying certain covenants. This development was formalized on Monday, with the company entering into the Tenth Amendment to its Credit Agreement.

The amendment pushes the termination date of the revolving credit facility to September 30, 2026, or an earlier date if certain conditions outlined in the agreement are met. This extension provides A-Mark with continued access to its credit line for nearly two additional years beyond the original termination date.

In addition to the extension, the Tenth Amendment also introduces changes to the covenants of the Credit Agreement. While the specific details of these modifications were not disclosed in the press release, such changes typically aim to adjust the company’s operational and financial flexibility within the scope of the credit facility.

A-Mark’s original Credit Agreement was established on December 21, 2021, and has since undergone several amendments leading up to this latest, the Tenth Amendment. CIBC Bank USA serves as the administrative agent for the lenders involved in this credit facility.

In other recent news, A-Mark Precious Metals has seen significant developments in its financial performance and business strategy. The company’s fiscal year results, ending June 30, 2024, reported a net income of $66.2 million, with diluted earnings per share (EPS) of $2.75.

After excluding a re-measurement gain from its investment in Silver Gold Bull, the diluted EPS was $2.15. Despite a 19% decrease in fourth-quarter revenues to $2.52 billion, A-Mark concluded the fiscal year with over $3 million direct-to-consumer customers and repurchased $22.4 million of its common stock.

Analysts from B.Riley and DA Davidson have shown confidence in A-Mark Precious Metals, raising their stock price targets to $44 and $47 respectively. B.Riley’s new forecast expects A-Mark Precious Metals to achieve an adjusted EBITDA of $31.6 million and earnings per share (EPS) of $0.91 for the first quarter of fiscal year 2025, up from its previous estimates. This optimism is based on the assumption of increased gold and silver pricing and improved sales volumes.

In strategic developments, A-Mark Precious Metals is contemplating expanding its market reach, potentially through a trading hub in Singapore. The company has also broadened its presence in Asia with the acquisition of LPM and increased its investment in Silver Gold Bull Canada.

Despite facing a 25% increase in interest expenses and a 54% decrease in full-year EBITDA compared to the previous fiscal year, A-Mark remains optimistic about potential M&A opportunities and maintaining profitability.

InvestingPro Insights

A-Mark Precious Metals’ recent amendment to its credit agreement aligns with the company’s strong financial performance and market position. According to InvestingPro data, A-Mark has demonstrated impressive growth with a 60.24% price total return over the past year and a substantial 46.43% return in the last six months. This positive momentum is further reflected in the company’s market capitalization of $1.03 billion.

InvestingPro Tips highlight that A-Mark’s stock price often moves in the opposite direction of the market, which could be advantageous for investors seeking portfolio diversification. Additionally, the company’s liquid assets exceed short-term obligations, suggesting a solid financial foundation that supports the extended credit facility.

While A-Mark suffers from weak gross profit margins, as noted by an InvestingPro Tip, the company remains profitable with a P/E ratio of 15.05, indicating reasonable valuation relative to earnings. This profitability, combined with the extended credit agreement, positions A-Mark well for potential future growth in the precious metals market.

For investors interested in a deeper analysis, InvestingPro offers 13 additional tips for A-Mark Precious Metals, providing a more comprehensive view of the company’s financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Continue Reading

Stock Markets

Camden National Corporation to Announce Quarter Ended September 30, 2024 Financial Results on October 29, 2024

letizo News

Published

on

CAMDEN, Maine, Oct. 2, 2024 /PRNewswire/ — Camden National (NASDAQ:) Corporation (NASDAQ: ) will report financial and operating results for the quarter ended September 30, 2024 on Tuesday, October 29, 2024.  A conference call and webcast will be held at 3:00 p.m. Eastern on Tuesday, October 29, 2024 hosted by Simon Griffiths, President and Chief Executive Officer and Michael Archer, Executive Vice President, Chief Financial Officer.

Parties interested in listening to the teleconference should dial into the call or connect to the webcast link 10 “ 15 minutes before it begins. Dial-in and webcast information to participate is as follows:

Live Dial-In (Domestic): (833) 470-1428
Live Dial-In (International): (929) 526-1599
Participant access code: 504894
Live Webcast URL:    https://events.q4inc.com/attendee/685424551

A link to the live webcast will be available on Camden National Corporation’s website at CamdenNationalCorporation.com  prior to the meeting. The transcript and replay of the conference call will also be made available on Camden National’s website following the conference call.

About Camden National Corporation

Camden National Corporation (NASDAQ: CAC) is Northern New England’s largest publicly traded bank holding company, with $5.7 billion in assets. Founded in 1875, Camden National Bank has 57 branches in Maine and New Hampshire, is a full-service community bank offering the latest digital banking, complemented by award-winning, personalized service. Additional information is available at CamdenNational.bank. Member FDIC. Equal Housing Lender.

Comprehensive wealth management, investment, and financial planning services are delivered by Camden National Wealth Management.

Continue Reading

Stock Markets

MESA LABS DECLARES QUARTERLY DIVIDEND

letizo News

Published

on

LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) —  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, Mesa or the Company) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.

About Mesa Laboratories (NASDAQ:), Inc.

Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

Forward Looking Statements

This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections.   Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words expect, anticipate, seek, intend, plan, believe, could, estimate, may, target, project, and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2024, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.

Continue Reading

Trending

©2021-2024 Letizo All Rights Reserved